Dong-A Vows Legal Steps As Korea Imposes Heavy Penalties Over Rebates
Korea temporarily suspends reimbursement of drugs involved in Dong-A ST’s alleged illegal rebate payments to doctors, raising concerns from the industry whether the new measures are appropriate. The company concedes it violated the Pharmaceutical Affairs Act but vows to seek legal redress as it claims there are substantial issues with the punitive measures.
You may also be interested in...
South Korea continues efforts to root out illegal rebate payments for drugs and to step up the pharma industry's ethics and social responsibility by revising relevant rules, but in a way that doesn't harm patients' health.
GemVax unveils positive topline results for South Korean Phase II study of novel peptide drug targeting patients with moderate to severe Alzheimer’s disease, raising hopes for the upcoming US trials.
Daewoong Pharmaceutical has successfully completed a Phase III clinical trial of next generation gastroesophageal reflux disease (GERD) drug candidate in South Korea, but strong competition awaits from approved P-CAB drugs of CJ Healthcare and Takeda.